Gleevec

Gleevec, known generically as imatinib and marketed internationally as Glivec, is a tyrosine kinase inhibitor used as a targeted therapy for certain cancers. It was developed by Novartis and represents a landmark achievement in oncology, transforming previously fatal leukemias into manageable chronic conditions for many patients. Its approval by the U.S. Food and Drug Administration in 2001 heralded a new era of rational drug design based on understanding specific molecular drivers of disease.

History and development

The development of Gleevec originated from research at Ciba-Geigy, which later merged with Sandoz to form Novartis. Scientists, including Nicholas Lydon and Brian Druker, targeted the BCR-ABL1 fusion protein, the constitutive tyrosine kinase responsible for chronic myelogenous leukemia. The compound, initially designated STI571, emerged from a chemical library screen and was optimized for potency and selectivity. Clinical trials, led by Druker at the Oregon Health & Science University, demonstrated unprecedented efficacy, leading to rapid FDA approval under the Priority Review and Orphan Drug Act designations. This journey from benchtop to bedside is often cited as a paradigm for translational research.

Mechanism of action

Gleevec functions as a competitive inhibitor at the adenosine triphosphate-binding site of specific tyrosine kinase enzymes. Its primary target is the BCR-ABL1 oncoprotein found in Philadelphia chromosome-positive CML. By binding to the inactive conformation of the kinase, it prevents autophosphorylation and subsequent downstream signal transduction pathways, such as those involving RAS and MAPK/ERK pathway, that drive uncontrolled cell proliferation. It also potently inhibits the receptor tyrosine kinase for platelet-derived growth factor and stem cell factor receptor (KIT), which is relevant for treating gastrointestinal stromal tumor.

Medical uses

Gleevec is indicated for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia in all phases (chronic phase, accelerated phase, blast crisis). It is also approved for Philadelphia chromosome-positive acute lymphoblastic leukemia, myelodysplastic syndrome with platelet-derived growth factor receptor gene rearrangements, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans. A major non-hematologic use is for gastrointestinal stromal tumors that express the KIT protein, where it has revolutionized management. Treatment is typically administered orally on a continuous daily schedule, with response monitored via techniques like polymerase chain reaction.

Adverse effects

Common adverse effects are often mild to moderate and include periorbital edema, nausea, muscle cramps, diarrhea, rash, and fatigue. More serious potential side effects involve myelosuppression, leading to neutropenia and thrombocytopenia, which require regular monitoring of complete blood count. Significant but less frequent risks include congestive heart failure, hepatotoxicity evidenced by elevated alanine transaminase, and fluid retention that can manifest as pleural effusion or ascites. Severe hemorrhage has been reported, particularly in patients with ALL.

Resistance and combination therapies

Resistance to Gleevec can develop through several mechanisms, most commonly point mutations in the BCR-ABL1 kinase domain (e.g., T315I mutation) that impair drug binding. Other mechanisms include gene amplification and activation of alternative signal transduction pathways. To overcome resistance, second-generation tyrosine kinase inhibitors like dasatinib, nilotinib, and bosutinib were developed, which bind to the kinase with different conformations. The T315I mutation remains resistant to most first- and second-line inhibitors but can be targeted by ponatinib. Combination therapies with chemotherapy or interferon alfa are also used in certain contexts.

Society and culture

Gleevec has had a profound societal impact, featured prominently in media such as Forbes and The New York Times, and was declared a "magic bullet" by Time (magazine). Its high cost sparked global debates on drug pricing and access to medicines, leading to legal battles over patent rights in countries like India. The drug's success story is a central case study in the value of basic research funded by institutions like the National Institutes of Health and has inspired patient advocacy groups like The Leukemia & Lymphoma Society. Its development earned researchers prestigious awards and reshaped the pharmaceutical industry's approach to oncology drug development. Category:Antineoplastic drugs Category:Tyrosine kinase inhibitors Category:World Health Organization essential medicines